Recent insights into extracorporeal photopheresis for graft-versus-host disease

References

• Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary Results N Engl J Med. 1987;316(6):297–303. doi: 10.1056/NEJM198702053160603
   PubMed Web of Science ®Google Scholar
• Tatsuno K, Yamazaki T, Hanlon D, et al. Extracorporeal photochemotherapy induces bona fide immunogenic cell death. Cell Death Dis. 2019;10(8):578. doi: 10.1038/s41419-019-1819-3
   PubMed Web of Science ®Google Scholar
• Sakellari I, Gavriilaki E, Batsis I, et al. Favorable impact of extracorporeal photopheresis in acute and chronic graft versus host disease: prospective single-center study. J Clin Apheresis. 2018;33(6):654–660. doi: 10.1002/jca.21660
   PubMed Web of Science ®Google Scholar
• Abu-Dalle I, Reljic T, Nishihori T, et al. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. Biol Blood Marrow Transplant. 2014;20(11):1677–1686. doi: 10.1016/j.bbmt.2014.05.017
   PubMed Web of Science ®Google Scholar
• Knobler R, Arenberger P, Arun A, et al. European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1. J Eur Acad Dermatol Venereol. 2020;34(12):2693–2716. doi: 10.1111/jdv.16890
   PubMed Web of Science ®Google Scholar
• Berger C, Hoffmann K, Vasquez JG, et al. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood. 2010;116(23):4838–4847. doi: 10.1182/blood-2009-11-256040
   PubMed Web of Science ®Google Scholar
• Salhotra A, Sandhu K, O’Hearn J, et al. A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease. Expert Rev Clin Immunol. 2023;19(3):241–251. doi: 10.1080/1744666X.2023.2152330
   PubMed Web of Science ®Google Scholar
• Biagi E, Di Biaso I, Leoni V, et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplant. (abbreviation). 2007;84(1):31–39. doi: 10.1097/01.tp.0000267785.52567.9c
   PubMed Web of Science ®Google Scholar
• Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood. 2008;112(4):1515–1521. doi: 10.1182/blood-2007-11-125542
   PubMed Web of Science ®Google Scholar
• Lopes SM, Roncon S, Pinho AC, et al. Should we use extracorporeal photopheresis more often? evidence from graft-versus-host disease patients monitored with treg as a biomarker. Future Sci OA. 2020;6(8):FSO623–FSO. doi: 10.2144/fsoa-2020-0107
   PubMed Web of Science ®Google Scholar
• Gandelman JS, Song DJ, Chen H, et al. A prospective trial of extracorporeal photopheresis for chronic graft-versus-host disease reveals significant disease response and no association with frequency of regulatory T cells. Biol Blood Marrow Transplant. 2018;24(12):2373–2380. doi: 10.1016/j.bbmt.2018.06.035
   PubMed Web of Science ®Google Scholar
• Denney HA, Whittle RJ, Lai J, et al. Regulatory T cells in chronic graft-versus-host disease after extracorporeal photopheresis: correlation with skin and global organ responses, and ability to taper steroids. Transplant. (abbreviation). 2017;101(1):204–211. doi: 10.1097/TP.0000000000001165
   PubMed Web of Science ®Google Scholar
• Wang L, Ni M, Hückelhoven-Krauss A, et al. Modulation of B cells and homing marker on NK cells through extracorporeal photopheresis in patients with steroid-refractory/Resistant graft-vs.-host disease without hampering anti-viral/Anti-leukemic effects. Front Immunol. 2018 Oct 8;9:2207. doi: 10.3389/fimmu.2018.02207
   PubMed Web of Science ®Google Scholar
• Ren HG, Adom D, Paczesny S. The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease. Expert Rev Clin Immunol. 2018;14(5):389–404. doi: 10.1080/1744666X.2018.1463159
   PubMed Web of Science ®Google Scholar
• Vajari MK, Moradinasab S, Yousefi AM, et al. Noncoding RNAs in diagnosis and prognosis of graft-versus-host disease (GVHD). J Cell Physiol. 2022;237(9):3480–3495. doi: 10.1002/jcp.30830
   PubMed Web of Science ®Google Scholar
• Montoya RT, López-Godino O, Garcia-Barbera N, et al. Identification of circulating microRNA signatures as potential noninvasive biomarkers for prediction to response to extracorporeal photoapheresis in patients with graft versus host disease. Blood. 2019;134(Supplement_1):4466. doi: 10.1182/blood-2019-121655
   Google Scholar
• Amat P, López-Corral L, Goterris R, et al. Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-vs-host disease after allogenic hematopoietic stem cell transplant. J Clin Apheresis. 2021;36(5):697–710. doi: 10.1002/jca.21918
   PubMed Web of Science ®Google Scholar
• Piccirillo N, Putzulu R, Massini G, et al. Mononuclear cell collection for extracorporeal photopheresis: concentrate characteristics for off-line UV-A irradiation procedure. J Clin Apheresis. 2018 Jun;33(3):217–221. Epub 2017 Aug 22. PMID: 28833438. doi: 10.1002/jca.21574
   PubMed Web of Science ®Google Scholar
• Helmberg W, Sipurzynski S, Groselje-Strehle A, et al. Does offline beat inline treatment: investigation into extracorporeal photopheresis. Transfus Med Hemother. 2020;47(3):198–204. doi: 10.1159/000506750
   PubMed Web of Science ®Google Scholar
• Radwanski K, Burgstaler E, Weitgenant J, et al. Pilot study of a new online extracorporeal photopheresis system in patients with steroid refractory or dependent chronic graft vs host disease. J Clin Apheresis. 2020;35(4):342–350. doi: 10.1002/jca.21804
   PubMed Web of Science ®Google Scholar
• Laulhé M, Lefebvre S, Le Broc-Ryckewaert D, et al. A standardized methodical approach to characterize the influence of key parameters on the in vitro efficacy of extracorporeal photopheresis. PLoS One. 2019 1;14(3):e0212835. doi: 10.1371/journal.pone.0212835
   PubMed Web of Science ®Google Scholar
• Franklin C, Bruderek K, Schilling B, et al. Chemoirradiated neutrophils and T cells differentially affect immune functions of APCs. J Leukocyte Biol. 2019;106(2):481–493. doi: 10.1002/JLB.5A0618-242R
   PubMed Web of Science ®Google Scholar
• Cid J, Carbassé G, Suárez-Lledó M, et al. Efficacy and safety of one-day offline extracorporeal photopheresis schedule processing one total blood volume for treating patients with graft-versus-host disease. Transfus (Abbreviation). 2019;59(8):2636–2642. doi: 10.1111/trf.15384
   PubMed Web of Science ®Google Scholar
• Gambichler T, Chatzipantazi M, Stranzenbach R, et al. Impact of extracorporeal photopheresis on blood and coagulation parameters. Dermatol Ther. 2022;35(5):e15366. doi: 10.1111/dth.15366
   PubMed Web of Science ®Google Scholar
• Hackstein H, Amoros JJ, Bein G, et al. Successful use of miniphotopheresis for the treatment of graft-versus-host disease. Transfus (Abbreviation). 2014;54(8):2022–7. doi: 10.1111/trf.12596
   PubMed Web of Science ®Google Scholar
• Verdú-Amorós J, Woessmann W, Maecker-Kolhoff B, et al. Mini photopheresis for refractory chronic graft-versus-host disease in children and adolescents. Transfus (Abbreviation). 2018;58(11):2495–2500. doi: 10.1111/trf.14880
   PubMed Web of Science ®Google Scholar
• Matic T, Bojanic I, Mazic S, et al. An automated mini buffy coat preparation method for use in mini extracorporeal photopheresis treatment of graft-vs-host-disease in a low body weight pediatric patient. J Clin Apheresis. 2019;34(4):468–473. doi: 10.1002/jca.21700
   PubMed Web of Science ®Google Scholar
• Perseghin P, Galimberti S, Balduzzi A, et al. Extracorporeal photochemotherapy for the treatment of chronic graft-versus-host disease: trend for a possible cell dose-related effect? Ther Apher Dial. 2007;11(2):85–93. doi: 10.1111/j.1744-9987.2007.00421.x
   PubMed Web of Science ®Google Scholar
• Bertani G, Santoleri L, Ferri U, et al. Response of steroid-refractory chronic graft-versus-host disease to extracorporeal photopheresis correlates with the dose of CD3+ lymphocytes harvested during early treatment cycles. Transfus (Abbreviation). 2016;56(2):505–510. doi: 10.1111/trf.13369
   PubMed Web of Science ®Google Scholar
• Worel N, Lehner E, Führer H, et al. Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter? Transfus (Abbreviation). 2018 Apr;58(4):1045–1053. doi: 10.1111/trf.14506
   PubMed Web of Science ®Google Scholar
• Del Fante C, Scudeller L, Viarengo G, et al. Response and survival of patients with chronic graft-versus-host disease treated by extracorporeal photochemotherapy: a retrospective study according to classical and national institutes of health classifications. Transfus (Abbreviation). 2012;52(9):2007–15. doi: 10.1111/j.1537-2995.2011.03542.x
   PubMed Web of Science ®Google Scholar
• Perotti C, Del Fante C, Tinelli C, et al. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. Transfu (Abbreviation). 2010;50(6):1359–1369. doi: 10.1111/j.1537-2995.2009.02577.x
   PubMed Web of Science ®Google Scholar
• FDA Examining Patient Deaths Associated With Extracorporeal Photopheresis Treatment. ASH clinical news. 2018 Apr.Available from: https://ashpublications.org/ashclinicalnews/news/3778/FDA-Examining-Patient-Deaths-Associated-With-Extracorporeal-Photopheresis
   Google Scholar
• Schwede K, Nagel S, Simon JC, et al. How to perform extracorporeal photopheresis via port catheter. Transfu (Abbreviation). 2017;57(11):2567–2570. doi: 10.1111/trf.14265
   PubMed Web of Science ®Google Scholar
• Adamski J. Vascular access considerations for extracorporeal photopheresis. Transfu (Abbreviation). 2018;58(Suppl1):590–597. doi: 10.1111/trf.14500
   PubMedGoogle Scholar
• Szymanski J, Shah P, Dynis M, et al. An ex vivo comparison of vascular access devices used in extracorporeal photopheresis. Transfu (Abbreviation). 2018;58(Suppl 1):609–613. doi: 10.1111/trf.14482
   PubMedGoogle Scholar
• Söderström A, Nørgaard MS, Thomsen AE, et al. Ultrasound-guidance of peripheral venous catheterization in apheresis minimizes the need for central venous catheters. J Clin Apheresis. 2020;35(3):200–205. doi: 10.1002/jca.21780
   PubMed Web of Science ®Google Scholar
• Pochon C, Reppel L, Halle P, et al. Cryopreservation as a way to maintain extracorporeal photopheresis regimen for GvHD treatment while circumventing patient temporary inability to undergo apheresis. Bone Marrow Transplant. 2017;52(1):167–170. doi: 10.1038/bmt.2016.240
   PubMed Web of Science ®Google Scholar
• Asensi Cantó P, Sanz Caballer J, Fuentes Socorro C, et al. Role of extracorporeal photopheresis in the management of children with graft-vs-host disease. J Clin Apheresis. 2022;37(6):573–583. doi: 10.1002/jca.22012
   PubMed Web of Science ®Google Scholar
• Sebastián E, Andrés Esteban EM, González-Vicent M, et al. Extracorporeal photopheresis in paediatric patients: a retrospective comparison between different ‘off-line’ protocols. Vox Sang. 2022;117(10):1220–1229. doi: 10.1111/vox.13346
   PubMed Web of Science ®Google Scholar
• Malard F, Holler E, Sandmaier BM, et al. Acute graft-versus-host disease. Nat Rev Dis Primers. 2023 8;9(1):27. doi: 10.1038/s41572-023-00438-1
   PubMedGoogle Scholar
• Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012 5;119(1):296–307. doi: 10.1182/blood-2011-06-364265
   PubMed Web of Science ®Google Scholar
• Gooptu M, Koreth J. Translational and clinical advances in acute graft-versus-host disease. Haematologica. 2020;105(11):2550–2560. doi: 10.3324/haematol.2019.240309
   PubMed Web of Science ®Google Scholar
• Patel DA, Crain M, Pusic I, et al. Acute Graft-versus-Host Disease: An Update on New Treatment Options. Drugs. 2023;83(10):893–907. doi: 10.1007/s40265-023-01889-2
   PubMed Web of Science ®Google Scholar
• Zeiser R, von Bubnoff N, Butler Jet al.REACH2 Trial GroupRuxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host DiseaseN Engl J Med. 2020 7; 382191800–1810. doi: 10.1056/NEJMoa1917635
   PubMed Web of Science ®Google Scholar
• Dall’amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher. 2002;6(4):296–304. doi: 10.1046/j.1526-0968.2002.00448.x
   PubMedGoogle Scholar
• Berger M, Albiani R, Sini B, et al. Extracorporeal photopheresis for graft-versus-host disease: the role of patient, transplant, and classification criteria and hematologic values on outcome-results from a large single-center study. Transfu (Abbreviation). 2015;55(4):736–47. doi: 10.1111/trf.12900
   PubMed Web of Science ®Google Scholar
• Sestili S, Eder S, Belhocine R, et al. F. Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: a single-center experience. Cytotherapy. 2020;22(8):445–449. doi: 10.1016/j.jcyt.2020.03.003
   PubMed Web of Science ®Google Scholar
• Connelly-Smith L, Alquist CR, Aqui NA, et al. Guidelines on the use of therapeutic Apheresis in clinical practice - evidence-based approach from the writing committee of the american society for Apheresis: the ninth special issue. J Clin Apheresis. 2023;38(2):77–278. doi: 10.1002/jca.22043
   PubMed Web of Science ®Google Scholar
• Castagna L, Morabito L, Mauro E, et al. First-line extracorporeal photochemotherapy for acute GVHD after unmanipulated haploidentical BMT following nonmyeloablative conditioning and post transplantation CY. Bone Marrow Transplant. 2014;49(2):317–318. doi: 10.1038/bmt.2013.174
   PubMed Web of Science ®Google Scholar
• Mehta RS, Bassett R, Rondon G, et al. Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant. 2021;56(6):1316–1324. doi: 10.1038/s41409-020-01188-4
   PubMed Web of Science ®Google Scholar
• Nygaard M, Karlsmark T, Andersen NS, et al. Extracorporeal photopheresis is a valuable treatment option in steroid-refractory or steroid-dependent acute graft versus host disease-experience with three different approaches. Bone Marrow Transplant. 2019 Jan;54(1):150–154. doi: 10.1038/s41409-018-0262-x
   PubMed Web of Science ®Google Scholar
• Zeiser R, Blazar BR, Longo DL. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377(26):2565–2579. doi: 10.1056/NEJMra1703472
   PubMed Web of Science ®Google Scholar
• Saidu NEB, Bonini C, Dickinson A, et al. New approaches for the treatment of chronic graft-versus-host disease: Current status and future directions. Front Immunol. 2020 9;11:578314. doi: 10.3389/fimmu.2020.578314
   PubMed Web of Science ®Google Scholar
• Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112(7):2667–74. doi: 10.1182/blood-2008-03-141481
   PubMed Web of Science ®Google Scholar
• Dignan FL, Greenblatt D, Cox M, et al. Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. Bone Marrow Transplant. 2012;47(6):824–830. doi: 10.1038/bmt.2011.186
   PubMed Web of Science ®Google Scholar
• UVADEX Chronic GVHD Study GroupGreinix HT, van Besien K, Elmaagacli, AH, et al. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis–results of a crossover randomized study. Biol Blood Marrow Transplant. 2011;17(12):1775–82. doi: 10.1016/j.bbmt.2011.05.004
   PubMed Web of Science ®Google Scholar
• Jagasia M, Scheid C, Socié G, et al.Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD. Blood Adv. 2019, 23;314: 2218–2229. doi: 10.1182/bloodadvances.2019000145
   PubMed Web of Science ®Google Scholar
• Bergeron A, Chevret S, Peffault de Latour R, et al. Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. Eur Respir J. 2018 3;51(5):1702617. doi: 10.1183/13993003.02617-2017
   PubMed Web of Science ®Google Scholar
• Grønningsæter IS, Tsykunova G, Lilleeng K, et al. Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment. Expert Rev Clin Immunol. 2017;13(6):553–569. doi: 10.1080/1744666X.2017.1279053
   PubMed Web of Science ®Google Scholar
• Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(7):1072–8. doi: 10.1016/j.bbmt.2010.11.018
   PubMed Web of Science ®Google Scholar
• Lucid CE, Savani BN, Engelhardt BG, et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transplant. 2011;46(3):426–429. doi: 10.1038/bmt.2010.152
   PubMed Web of Science ®Google Scholar
• Brownback KR, Simpson SQ, Pitts LR. Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation. J Clin Apheresis. 2016;31(4):347–352. doi: 10.1002/jca.21404
   PubMed Web of Science ®Google Scholar
• Del Fante C, Galasso T, Bernasconi P, et al. Extracorporeal photopheresis as a new supportive therapy for bronchiolitis obliterans syndrome after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51(5):728–731. doi: 10.1038/bmt.2015.324
   PubMed Web of Science ®Google Scholar
• Hefazi M, Langer KJ, Khera N, et al. Extracorporeal photopheresis improves survival in hematopoietic cell Transplant patients with bronchiolitis obliterans syndrome without significantly impacting measured pulmonary functions. Biol Blood Marrow Transplant. 2018;24(9):1906–1913. doi: 10.1016/j.bbmt.2018.04.012
   PubMed Web of Science ®Google Scholar
• Ali MM, Gedde-Dahl T, Osnes LT, et al. Extracorporeal photopheresis as graft-versus-host disease prophylaxis: a randomized controlled trial. Transplant Cell Ther. 2023;29(6):364.e1–364.e11. doi: 10.1016/j.jtct.2023.02.023
   PubMedGoogle Scholar
• Shaughnessy PJ, Bolwell BJ, van Besien K, et al. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45(6):1068–1076. doi: 10.1038/bmt.2009.307
   PubMed Web of Science ®Google Scholar
• Michallet M, Sobh M, Garban F, et al. Extracorporeal photopheresis for GVHD prophylaxis after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation: a prospective multicenter phase 2 study. Leuk Lymphoma. 2018;59(2):372–380. doi: 10.1080/10428194.2017.1334120
   PubMed Web of Science ®Google Scholar
• Kitko CL, Braun T, Couriel DR, et al. Combination therapy for graft-versus-host disease prophylaxis with etanercept and extracorporeal photopheresis: results of a phase II clinical trial. Biol Blood Marrow Transplant. 2016;22(5):862–868. doi: 10.1016/j.bbmt.2015.11.002
   PubMed Web of Science ®Google Scholar
• Abdelhakim H, Accurso A, Merkel D, et al. Peri-transplant extracorporeal photopheresis to mitigate GVHD- a pilot clinical trial. Bone Marrow Transplant. 2021;56(4):980–982. doi: 10.1038/s41409-020-01142-4
   PubMed Web of Science ®Google Scholar
• FM F, XV W, SM L, et al. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfu (Abbreviation). 2020;60(8):1867–1872. doi: 10.1111/trf.15798
   PubMed Web of Science ®Google Scholar
• Malard F, Mohty M. Updates in chronic graft-versus-host disease management. Am J Hematol. 2023;22(10):1637–1644. Epub ahead of print. doi: 10.1002/ajh.27040
   Google Scholar
• Modemann F, Ayuk F, Wolschke C, et al. Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level. Bone Marrow Transplant. 2020;55(12):2286–2293. doi: 10.1038/s41409-020-0952-z
   PubMed Web of Science ®Google Scholar
• Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062–2068. doi: 10.1038/leu.2015.212
   PubMed Web of Science ®Google Scholar
• Maas-Bauer K, Kiote-Schmidt C, Bertz H, et al. Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease. Bone Marrow Transplant. 2021;56(4):909–916. doi: 10.1038/s41409-020-01122-8
   PubMed Web of Science ®Google Scholar
• Pierelli L, Perseghin P, Marchetti M, et al. Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian society of Hemapheresis and cell manipulation (SIdEM) and Italian group for Bone Marrow transplantation (GITMO) consensus process. Transfu (Abbreviation). 2013;53(10):2340–2352. doi: 10.1111/trf.12059
   PubMed Web of Science ®Google Scholar
• Belizaire R, Kim HT, Poryanda SJ, et al. Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Adv. 2019;3(7):969–979. doi: 10.1182/bloodadvances.2018029124
   PubMed Web of Science ®Google Scholar
• Salhotra A, Talley M, Wu X, et al. Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host disease. Bone Marrow Transplant. 2022;57:1045–47. doi: 10.1038/s41409-022-01671-0
   PubMed Web of Science ®Google Scholar
• Yalniz FF, Murad MH, Lee SJ, et al. Steroid refractory chronic graft-versus-host disease: cost-effectiveness analysis. Biol Blood Marrow Transplant. 2018;24(9):1920–1927. doi: 10.1016/j.bbmt.2018.03.008
   PubMed Web of Science ®Google Scholar
• Lopes SM, Roncon S, Pinho AC, et al. Should we use extracorporeal photopheresis more often? Evidence from graft-versus-host disease patients monitored with Treg as a biomarker. Future Sci OA. 2020 10;6(8):FSO623. doi: 10.2144/fsoa-2020-0107
   PubMed Web of Science ®Google Scholar
• Buchele V, Hackstein H. A simplified extracorporeal photopheresis procedure based on single high-dose ultraviolet a light irradiation shows similar in vitro efficacy. Transfu (Abbreviation). 2021 Mar;61(3):883–893. Epub 2020 Dec 10. PMID: 33300629. doi: 10.1111/trf.16209
   PubMed Web of Science ®Google Scholar
• Reschke R, Zimmerlich S, Döhring C, et al. Effective extracorporeal photopheresis of patients with transplantation induced acute intestinal GvHD and bronchiolitis obliterans syndrome. Biomedicines. 2022 4;10(8):1887. doi: 10.3390/biomedicines10081887
   PubMed Web of Science ®Google Scholar
• Del Fante C, Scudeller L, Oggionni T, et al. Long-term off-line extracorporeal photochemotherapy in patients with chronic lung allograft rejection not responsive to conventional treatment: a 10-year single-centre analysis. Respiration. 2015;90(2):118–128. doi: 10.1159/000431382
   PubMed Web of Science ®Google Scholar
• Del Fante C, Perotti C. Extracorporeal photopheresis for bronchiolitis obliterans syndrome after allogeneic stem cell transplant: an emerging therapeutic approach? Transfus Apher Sci. 2017;56(1):17–19. doi: 10.1016/j.transci.2016.12.010
   PubMed Web of Science ®Google Scholar